



**RPG LIFE SCIENCES LIMITED**  
Regd. Off.: RPG House  
463, Dr. Annie Besant Road  
Worli, Mumbai 400030, India  
Tel: +91-22-24981650 / 66606375  
Fax: +91-22-24970127  
Email: info@rpglifesciences.com  
www.rpglifesciences.com  
CIN : L24232MH2007PLC169354

January 24, 2025

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor,  
Plot No. C-1, G- Block,  
Bandra - Kurla Complex, Bandra (East)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

**Sub: Press Release - Financial Results**

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended December 31, 2024.

Kindly take the above on record.

Thanking you,

Yours Sincerely,  
For RPG Life Sciences Limited

Rajesh Shirambekar  
Head – Legal & Company Secretary

Encl.: as above



## Q3 FY25: Revenue Up by 12% Y-o-Y, PBT Surges 32% Y-o-Y, EBITDA Margin Jumps from 25.9% to 30.4% Y-o-Y.

**Mumbai, 24 January, 2025:** RPG Life Sciences Limited has announced its financial results for the third quarter and nine months ended December 31, 2024.

	Y-o-Y Revenue from operations	Y-o-Y PBT before exceptional items
Q3 FY25 Highlights	Rs. 172.71 crores – up from Rs. 153.70 crores	Rs. 46.89 crores – up from Rs. 35.54 crores
9M FY25 Highlights	Rs. 510.34 crores – up from Rs. 455.06 crores	Rs. 125.28 crores – up from Rs. 100.10 crores

RPG Life Sciences, a part of RPG Enterprises, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT before exceptional items by 32% Y-o-Y and by 11% Q-o-Q for Q3 FY25, maintaining the upward trajectory in EBITDA margins, which improved from 25.9% to 30.4% Y-o-Y and from 27.8% to 30.4% Q-o-Q. Revenue from operations registered a growth of 12% Y-o-Y and a flat growth Q-o-Q for Q3 FY25. For 9M FY25 too, the company posted a jump in PBT before exceptional items by 25% Y-o-Y and recorded EBITDA margin expansion from 24.8% to 27.8% Y-o-Y. Revenue from operations at Rs. 510.34 crores registered a growth of 12% Y-o-Y for 9M FY25.

**Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.** said, “In Q3 FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 32% respectively Y-o-Y. EBITDA margin surged from 25.9% to 30.4% Y-o-Y retaining its upward trajectory Y-o-Y for the last more than 5 years. The Company continues to remain debt-free.

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five pillar strategy – product portfolio rejuvenation, building strategic brand/portfolio assets, sales force excellence and productivity enhancement, customer engagement through medico-marketing initiatives and continued cost efficiency drive.

We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory.

Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.”

### **RPG Life Sciences Ltd ([www.rpglifesciences.com](http://www.rpglifesciences.com)):**

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

### **RPG Group ([www.rpggroup.com](http://www.rpggroup.com)):**

RPG Group, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4.8 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

### **Media Contact:**

Rashmi Menon – 88980 20577 | [rashmi@rpg.in](mailto:rashmi@rpg.in)



An  **RPG** Company